
Portfolio simulation may be an effective tool to forecast achievability of COVID-19 portfolio strategic goals, including risk mitigation to boost vaccines development and production.
Portfolio simulation may be an effective tool to forecast achievability of COVID-19 portfolio strategic goals, including risk mitigation to boost vaccines development and production.
Policymakers should break with drug and biotech norms and apply risk-based portfolio simulations to understand the global portfolio of COVID-19 vaccines.
Optimization model evaluates the benefits of selecting a portfolio of investigative sites based on advanced analytical models.
Site selection is one of the most important and at the same time challenging problems in clinical trials planning. Poor site selection may cause enrollment delays, resource waste on low or zero enrollment, and even potentially compromise trial results.
Published: February 13th 2025 | Updated: March 4th 2025
Published: February 19th 2025 | Updated: February 26th 2025
Published: March 24th 2023 | Updated:
Published: April 28th 2021 | Updated:
Published: July 26th 2024 | Updated:
Published: January 31st 2024 | Updated: